Black Health logo Black Health
News

WHO declares Bundibugyo Ebola outbreak in DRC and Uganda a global emergency; no licensed vaccine exists

Black Health Editorial team
12 min read

Evidence-based

Written by the Black Health editorial team. Last updated . How we source.

A Black male physician in a white lab coat and red tie reviews a green chart folder with a Black female nurse in blue scrubs in a hospital corridor with an EMERGENCY sign visible to the left.
A Black male physician in a white lab coat and red tie reviews a green chart folder with a Black female nurse in blue scrubs in a hospital corridor with an EMERGENCY sign visible to the left. Photo: RDNE Stock project / Pexels
On 16 May, the WHO Director-General named the Bundibugyo Ebola outbreak in DRC and Uganda a public health emergency of international concern. The CDC situation summary as of 23 May reports 746 suspected cases and 176 suspected deaths in DRC, and 5 confirmed cases including 1 death in Uganda in people who traveled from DRC. No licensed Bundibugyo vaccine; one American healthcare worker transported to Germany for treatment and care.

The WHO Director-General declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern on 16 May 2026, with 246 suspected cases and 80 deaths reported as of 15 May (WHO Disease Outbreak News 602). Four of those deaths were among confirmed cases. The CDC situation summary as of 23 May 2026 reports a total of 746 suspected cases, 83 confirmed cases, 176 suspected deaths, and 9 confirmed deaths in DRC, plus 5 confirmed cases and 1 confirmed death in Uganda in people who traveled from DRC (CDC Ebola situation summary). The WHO declaration also states verbatim that there is "no licensed vaccine or specific therapeutics against Bundibugyo virus," a status that separates this outbreak from the Zaire-ebolavirus outbreaks for which Merck's Ervebo carries US Food and Drug Administration licensure.

The outbreak is concentrated in three health zones of DRC's Ituri Province: Rwampara, with six health areas affected; Mongbwalu, with three; and Bunia (WHO DON602). Cross-border transmission has already produced 5 confirmed cases and 1 confirmed death in Uganda, all in travelers from DRC with no further spread reported (CDC Ebola situation summary, as of 23 May 2026). The peer-reviewed primate literature documents Bundibugyo virus mortality at approximately 20 to 51 percent (Woolsey et al., J Infect Dis 2023, PMID 37290053).

The Bundibugyo vaccine gap is a 14-year pipeline failure, not a knowledge gap

Merck's Ervebo is licensed in the United States only against Zaire ebolavirus, the species behind the 2014-2016 West Africa outbreak and the 2018-2020 DRC outbreaks. The Bundibugyo strain spreading in DRC and Uganda right now is genetically distinct. Cross-protection between Ervebo and Bundibugyo has been on the primate-evidence record for 14 years and has never produced a licensed Bundibugyo-specific product.

The foundational paper sits in the Journal of Infectious Diseases. A 2011 nonhuman-primate study by Falzarano and colleagues showed that a single immunization with a monovalent vesicular stomatitis virus vector expressing Bundibugyo glycoprotein protected primates against lethal heterologous challenge (Falzarano et al., J Infect Dis 2011, PMID 21987745). A 2023 postexposure proof-of-concept by Woolsey and colleagues at the University of Texas Medical Branch in Galveston and Boston University extended the primate evidence: a recombinant vesicular stomatitis virus vaccine carrying Bundibugyo glycoprotein, delivered after exposure, conferred a survival benefit in the primate model (Woolsey et al., J Infect Dis 2023, PMID 37290053). Both studies remain proof-of-concept. No licensure path has closed in the years since.

The pan-ebolavirus monoclonal-antibody pipeline is the most plausible near-term Bundibugyo therapeutic class. A 2022 Cell study tested a two-antibody cocktail in primates and reported complete protection against the Zaire and Sudan species; Bundibugyo-specific efficacy was not the primary abstract finding (Milligan et al., Cell 2022, PMID 35303429). None of these candidates is licensed for Bundibugyo.

CDC enhanced US surveillance: 21-day window, port-of-entry screening, one American transported to Germany

CDC's 18 May 2026 newsroom briefing announced enhanced US surveillance attributed verbatim to CAPT Satish K. Pillai, MD, MPH, Incident Manager for CDC's Ebola Response. The protocol covers three measures: "enhancing public health screening and traveler monitoring for individuals arriving from the DRC, Uganda and South Sudan," "putting entry restrictions on non-U.S. passport holders if they have been in Uganda, DRC, or South Sudan in the previous 21 days," and "enhancing port health protection response activities, contact tracing, laboratory testing capacity, and hospital readiness nationwide" (CDC newsroom transcript, 18 May 2026).

CDC's 19 May HAN-00530 layers the clinical-facility protocol on top: a 21-day exposure-assessment window before symptom onset, immediate isolation for any patient with both an exposure risk and Bundibugyo-compatible symptoms, and serial specimen testing until a specimen collected at least 72 hours after symptom onset returns negative (CDC HAN-00530, 19 May 2026).

The US case count is verbatim from the HAN: "As of May 18, no suspected, probable, or confirmed Ebola cases related to this outbreak have been reported in the United States" (CDC HAN-00530). The CDC situation summary as of 23 May restates verbatim that "no cases of Ebola disease have been confirmed in the United States because of this outbreak" (CDC Ebola situation summary). A US healthcare worker exposed during clinical work in DRC tested positive and was announced in the CDC's 18 May briefing; per the CDC situation summary as of 23 May, "the patient has been transported to Germany for treatment and care," and high-risk contacts associated with the exposure have been moved to Germany and the Czech Republic (CDC Ebola situation summary). No US-soil cases have been reported.

HHS aid to DRC fell from $33 million to under $10 million between FY24 and FY25

A 19 May 2026 STAT News investigation by Daniel Payne documents the dollar trail behind a degrading outbreak response in DRC. HHS direct foreign-aid disbursement to DRC fell from "nearly $33 million" in fiscal year 2024 to "less than $10 million in 2025," per STAT's reporting. The US Agency for International Development sent "some $67 million in foreign aid to the country in the final three months of 2025, down from $715 million in fiscal 2025 and nearly $1.2 billion in fiscal 2024" (Payne, STAT News, 19 May 2026).

STAT names the operational consequence verbatim: the International Rescue Committee "reduced programming from five to two areas at the heart of the current outbreak after U.S. cuts." Heather Reoch Kerr, IRC Country Director for DRC, told STAT: "Preparedness in high-risk areas is critical to disrupting transmission before the outbreak spreads further. Years of underinvestment and recent funding cuts have left many health facilities without adequate protective equipment, surveillance capacity, or front-line support needed to respond quickly and safely" (Payne, STAT News). Daniel Jernigan, a 30-year CDC veteran, told STAT of the agency's working proximity to USAID: "We were sitting next to the USAID people the whole time. Those cuts are going to have an effect no matter what the situation is" (Payne, STAT News).

The mechanism is upstream containment. Containment failure in DRC raises the probability of regional exportation, which WHO names in DON602 as a heightened risk given Ituri Province's geographic position.

Primate evidence is the only ground for any Ervebo deployment decision

Public-health officials are weighing whether to deploy Ervebo against the Bundibugyo strain on the strength of small primate cross-protection signals. STAT reporter Helen Branswell summarized the data in an 18 May piece: a small study showed "three of four previously vaccinated animals survived exposure to the virus, compared to one of three unvaccinated animals" (Branswell, STAT News, 18 May 2026). Tom Geisbert, the senior virologist on that study and the Galveston National Laboratory principal investigator named on the Woolsey and Falzarano papers, told STAT verbatim: "When you get three out of four survivors, we've got to factor in that some of those survivors may have survived without the [vaccine]" (Branswell, STAT News).

Vasee Moorthy of the WHO R&D Blueprint told STAT that "any decision as to next steps will be for DRC and Uganda, supported by WHO" (Branswell, STAT News). A Merck spokesperson, also in Branswell's reporting, said: "the data are limited, not from humans and not from evaluation of Ervebo." Any deployment decision in the next 30 days will be made on this primate-only evidence base, not on randomized human data.

A US-soil Bundibugyo exposure most plausibly enters a Black-serving safety-net emergency department

A US-soil exposure presenting symptoms during the CDC 21-day clinical-recognition window would most plausibly arrive in a metropolitan area with substantial Congolese, Ugandan, or South Sudanese diaspora communities, and through a clinical front door that absorbs uninsured and Medicaid-covered patients. Howard University Hospital in Washington DC, Grady Memorial Hospital in Atlanta, and MetroHealth in Cleveland are three Black-serving safety-net institutions in cities with substantial East- and Central-African diaspora populations.

The structural equation has two sides. The dollar trail Payne documents at the upstream end, HHS and USAID disbursements to DRC falling by roughly two-thirds and 95 percent respectively between FY24 and FY25, is the proximate driver of any containment failure that produces diaspora-receiving transmission risk. The Black-serving safety-net hospitals at the downstream end carry the clinical-recognition burden, and they are exactly the institutions funded least well to absorb a high-acuity isolation case. Containment dollars and emergency-department triage capacity are halves of the same equation.

We have asked Howard and Grady infection-prevention leads for an on-the-record statement on Bundibugyo-specific readiness. That reporting will run as an update if and when those statements arrive.

What you can do this week

If you are traveling from DRC, Uganda, or South Sudan in the next 30 days, the CDC's 21-day exposure-assessment window will follow you for three weeks after your return. Be prepared to disclose your travel history at any US emergency-department or clinic visit during that period, and ask any treating clinician to consult CDC HAN-00530 before ordering routine testing. The HAN is at https://www.cdc.gov/han/php/notices/han00530.html.

If you are an emergency-department or triage clinician at a Black-serving safety-net institution, the HAN is the verbatim clinical-recognition protocol you will be expected to apply. The 72-hour specimen-testing window is load-bearing: a single negative specimen taken before that point does not rule out Bundibugyo virus disease, and the patient must remain isolated until a specimen collected at least 72 hours after symptom onset returns negative (CDC HAN-00530). Bookmark it. If your facility has not run a tabletop on a febrile-returning-traveler scenario in 2026, ask your infection-prevention lead to schedule one in the next two weeks.

If you are a community health worker or a faith-community health minister in a diaspora-receiving metro, the WHO DON602 page is the official outbreak update channel; check it weekly through the end of June. Recent travelers in your community will benefit from knowing that disclosing a 21-day travel history at any clinic visit is the most direct way to protect both themselves and the staff treating them.

Citations

Medical Disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Newsletter

One email a week with essential Black health news, plus a featured provider.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Follow Black Health for more

Facebook Instagram LinkedIn

Share this article

Twitter LinkedIn Facebook

More from Black Health Editorial team

Trending Health Topics

Black LGBTQ+ Health Black Women's Health Black Men's Health Kids and Teens Seniors